
Sign up to save your podcasts
Or


A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.
By The Motley Fool4.5
825825 ratings
A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.

3,217 Listeners

808 Listeners

944 Listeners

1,604 Listeners